Literature DB >> 1379418

Life-threatening anaphylactoid reactions to propofol (Diprivan)

M C Laxenaire1, E Mata-Bermejo, D A Moneret-Vautrin, J L Gueant.   

Abstract

Fourteen patients who had had a life-threatening reaction within a few minutes after receiving propofol (Diprivan) were investigated for anaphylaxis 4-6 weeks after the incident. Three kinds of immunologic tests were carried out: skin tests (prick tests and intradermal tests with the drugs used and Intralipid, the solvent for propofol), a leukocyte histamine release test, and a radioimmunoassay (RIA) of immunoglobulin E (IgE) against propofol and muscle relaxants, when they had been given with propofol. It had been previously shown that these were always negative in patients anesthetized with propofol without any complications. Thirteen of the 14 patients had at least one positive test supporting hypersensitivity to propofol; 2 patients had three tests positive; 4 had two tests positive; and 7 had one test positive. The skin tests with Intralipid were negative in 4 patients whose tests with propofol were positive. Two patients who had been given muscle relaxants at the same time as the propofol had positive IgE-RIA to both drugs. In one patient, results of all the tests remained negative, and the mechanism involved in the reaction remained unidentified. It is note-worthy that 9 patients of 14 had allergic histories that were known before the anesthetic (atopy; allergy to antibiotics, muscle relaxants, lidocaine, colloids) and that none of the patients had ever received propofol or Intralipid before. It is possible that the IgE that linked abnormally with the propofol had specific binding sites for the phenyl nucleus and the isopropyl groups, which are present in propofol and many other drugs.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1379418     DOI: 10.1097/00000542-199208000-00009

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  23 in total

Review 1.  Sedation and analgesia in paediatric intensive care units: a guide to drug selection and use.

Authors:  J D Tobias
Journal:  Paediatr Drugs       Date:  1999 Apr-Jun       Impact factor: 3.022

Review 2.  Comparative tolerability of sedative agents in head-injured adults.

Authors:  Susan C Urwin; David K Menon
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 3.  Prevention of anaphylactic reactions to anaesthetic drugs.

Authors:  Malcolm M Fisher; Gordon S Doig
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

4.  Propofol Use in Pediatric Patients With Food Allergy and Eosinophilic Esophagitis.

Authors:  Pooja Mehta; Shikha S Sundaram; Glenn T Furuta; Zhaoxing Pan; Dan Atkins; Scott Markowitz
Journal:  J Pediatr Gastroenterol Nutr       Date:  2017-04       Impact factor: 2.839

Review 5.  New iv induction anaesthetics.

Authors:  D H Morison
Journal:  Can J Anaesth       Date:  1993-05       Impact factor: 5.063

6.  [Live-threatening bronchospasm during anesthesia induction : when pure routine becomes a nightmare].

Authors:  A Rüggeberg; J Breckwoldt
Journal:  Anaesthesist       Date:  2011-09-16       Impact factor: 1.041

7.  Use of an anesthesia information management system (AIMS) to evaluate the physiologic effects of hypnotic agents used to induce anesthesia.

Authors:  M Benson; A Junger; C Fuchs; L Quinzio; S Böttger; G Hempelmann
Journal:  J Clin Monit Comput       Date:  2000       Impact factor: 2.502

Review 8.  Propofol in patients with cardiac disease.

Authors:  N R Searle; P Sahab
Journal:  Can J Anaesth       Date:  1993-08       Impact factor: 5.063

9.  My patient is allergic to eggs, can i use propofol? A case report and review.

Authors:  Jamal Tashkandi
Journal:  Saudi J Anaesth       Date:  2010-09

Review 10.  Propofol. An update of its use in anaesthesia and conscious sedation.

Authors:  H M Bryson; B R Fulton; D Faulds
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.